Stayble Therapeutics publishes interim report for the third quarter 2022
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the interim report for the third quarter of 2022. The report is available as an attached document and on the Company's website.Highlights during the third quarter (July – September 2022) · Stayble announces that the last patient has been enrolled in the ongoing Phase 2b clinical trial of STA363 for chronic disc-related low back pain. This completes patient enrolment, and the study will be completed once all patients have been followed up for 12 months. Top-line results are expected to be presented in Q4 2023. ·